Conditions: Colorectal Neoplasms Lung Neoplasms Breast Neoplasms Prostatic Neoplasms Sarcoma
Keywords: advanced solid tumors cancer refractory cancer figitumumab pegvisomant
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 24
Healthy volunteers: no

Brief summary:
This is a Phase 1 study investigating the safety and tolerability of Figitumumab plus Pegvisomant for treatment of advanced solid tumors.

Detailed description:
This study was closed to enrollment on 18 April 2011 due to inability to recruit patients on a timely basis as well as business reasons. Study closure was not related to any safety concerns.

Arms:
arm 1: None

Interventions: intervention 1: figitumumab intervention 2: pegvisomant
Intervention descriptions: intervention 1: IGF-1R antibody, 20 mg/kg, IV every 3 weeks for up to 1 year intervention 2: growth hormone antagonist, 10, 20 or 30 mg per day via subcutaneous injection for up to 1 year

Protocol document: